Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells. By blocking CD117, briquilimab is intended to reduce or remove existing stem cells and mast cells, potentially creating space for transplanted or genetically modified cells while reducing the need for intensive chemotherapy-based conditioning.

The company has evaluated briquilimab in clinical programs involving hematopoietic stem-cell transplantation and gene therapy, as well as diseases associated with abnormal mast-cell activity, including chronic urticaria. Jasper Therapeutics is headquartered in Redwood City, California, and conducts development activities through clinical studies and collaborations in the United States and other regions. Its products remain investigational and have not been established as approved therapies based on the company’s publicly described pipeline.

Key Stats

• Today's Range: $0.46 to $0.52
• 50-Day Range: $0.50 to $0.89
• 52-Week Range: $0.32 to $2.69
• Volume: 616,389 shs
• Average Volume: 822,733 shs
• Market Capitalization: $16.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Hold

Jasper Therapeutics Stock Analysis - MarketRank™

Jasper Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 726th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Jasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Jasper Therapeutics has a consensus price target of $7.33, representing about 1,453.7% upside from its current price of $0.47.

Amount of Analyst Coverage

Jasper Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Jasper Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jasper Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jasper Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jasper Therapeutics has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.45% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Jasper Therapeutics has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jasper Therapeutics does not currently pay a dividend.

Dividend Growth

Jasper Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.47

News Sentiment

Jasper Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Jasper Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.90% of the stock of Jasper Therapeutics is held by insiders.

Percentage Held by Institutions

79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:JSPR
• CIK: 1788028
• Web: jaspertherapeutics.com
• Phone: 650-549-1400
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jasper Therapeutics: $7.33
• High Price Target: $17.00
• Low Price Target: $2.00
• Potential Upside/Downside: +1,363.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -884.17%
• Return on Assets: -143.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.48
• Quick Ratio: 1.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 33,280,000
• Free Float: 31,977,000
• Market Cap: $16.67 million
• Optionable: Optionable
• Beta: 3.16